Tranexamic Acid Use for Massive Hemoptysis in a Child: A Case Report

• Published in: Curēus (Palo Alto, CA) Vol. 14; no. 8
• Main Author: Mazi, Ahlam
• Format: Journal Article
• Language: English
• Published: Palo Alto Cureus Inc 19-08-2022; Cureus
• Subjects: Antifibrinolytic agents; Case reports; Emergency Medicine; Hemoptysis; Medical imaging; Mortality; Pediatrics; Pulmonology; Tuberculosis; Veins & arteries
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.28186

Massive hemoptysis is a rare life-threatening condition in children. Individuals with non-cystic fibrosis bronchiectasis may present with various degrees of hemoptysis. Therapeutic measures are mainly derived from studies involving adults or various case reports of children with cystic fibrosis. The standard management of massive hemoptysis is limited to invasive bronchoscopy, bronchial artery embolization, and surgical resection. Tranexamic acid (TXA) use is limited to non-massive hemoptysis or as an adjuvant and temporizing measure before definitive treatment. We report the potential use of TXA as an emergency treatment for massive hemoptysis in a 10-year-old boy with non-cystic fibrosis bronchiectasis and chronic infection. The use of systemic TXA (250 mg every eight hours for five days) successfully stopped active bleeding beginning from the first dose and altered the need for invasive interventions. Although he experienced another episode of massive hemoptysis because of pneumonia and pulmonary exacerbation, invasive measures were not required because he responded to systemic TXA immediately. Moreover, no further recurrence of hemoptysis was noted on cessation of TXA and throughout two years of regular follow-up. Therefore, TXA could be considered a non-invasive therapy for children with massive hemoptysis, especially in the absence of standard invasive therapies.